Compare Alcon AG (ALC) vs Arm Holdings plc (ARM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Arm Holdings plc — how do they compare? Alcon AG trades at $66.81 (market cap $32.69B), while Arm Holdings plc trades at $296.31 (market cap $320.88B). The key difference: Arm Holdings plc is far larger — about 9.8× Alcon AG's market cap, and Alcon AG pays a 0.54% dividend while Arm Holdings plc pays none. Which is the better fit depends on your goals.
| ALC | ARM | |
|---|---|---|
Market Cap | $32.69B | $320.88B |
Sector | Health | Technology |
52-Week High | $92.22 | $439.46 |
52-Week Low | $62.02 | $104.55 |
Enterprise Value | $36.28B | $317.74B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ARM Holdings trades at $322.24, up 2.21% today but showing bearish technical momentum with key support at $317. The stock maintains strong fundamentals with 97.54% gross margins and consistent earnings beats, though valuation ratios remain elevated (P/E 379.11). Recent news highlights AI-driven growth in licensing and data center expansion, despite a 35% pullback from June 2026 peaks.
Outlook is mixed: robust AI demand and analyst optimism (74% buy ratings) support upside potential, but high valuation and technical weakness pose near-term risks. The consensus price target of $321.65 aligns with current levels, suggesting cautious optimism amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →
